Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00766337 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Combination With Lucentis® in Patients With Age-Related Macular Degeneration
A Phase 2 study, sponsored by Santen.
- Terminated
- Registry status
- Phase 2
- Development phase
- 62
- Enrollment target
NCT00766337 is a Phase 2 study that was terminated before completion, run by Santen. The registered enrollment target is 62 participants.
The verdict
NCT00766337, a Phase 2 study, was terminated before completion, sponsored by Santen.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 62 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and efficacy of an ocular sirolimus (rapamycin) formulation in combination with Lucentis in patients with sub-foveal choroidal neovascularization secondary to age-related macular degeneration.
Interventions
- DRUG Sirolimus in combination with ranibizumab
- DRUG Placebo in combination with ranibizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2008-12 |
| Est. Completion | 2010-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00766337
The ClinicalTrials.gov registry entry for NCT00766337 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Santen, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sirolimus in combination with ranibizumab is the first listed.
NCT00766337 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00766337 about?
NCT00766337 is a clinical study titled "Phase 2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Combination With Lucentis® in Patients With Age-Related Macular Degeneration". The purpose of this study is to determine the safety and efficacy of an ocular sirolimus (rapamycin) formulation in combination with Lucentis in patients with sub-foveal choroidal neovascularization secondary to age-related macular degeneration.
What is the current status of trial NCT00766337?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 62 participants. The study started on 2008-12. Estimated completion is 2010-03.
What interventions are being tested in trial NCT00766337?
The interventions under investigation include: Sirolimus in combination with ranibizumab (DRUG), Placebo in combination with ranibizumab (DRUG).
Who is sponsoring clinical trial NCT00766337?
This trial is sponsored by Santen, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.